Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Searle CoKAR:SEARL +2.00%73 EBITDA Margin % is 16.04% as of Mar. 2026, which is 27% below its 10-year median of 22.04. GuruFocus rates KAR:SEARL with a GF Score™ of 73/100 and a GF Value™ of ₨76.13 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, The Searle Co ranks better than 67.53% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. The Searle Co's EBITDA for the
three
months ended in Mar. 2026 was ₨1,561 Mil. The Searle Co's Revenue for the
three
months ended in Mar. 2026 was ₨9,734 Mil. Therefore, The Searle Co's EBITDA margin for the quarter that ended in Mar. 2026 was 16.04%.
The Searle Co (KAR:SEARL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
The Searle Co EBITDA Margin % Related Terms
The Searle Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for The Searle Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:SEARL vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, The Searle Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Searle Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The Searle Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where The Searle Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Searle Co (KAR:SEARL) has a EBITDA Margin % of 16.04% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on The Searle Co and its competitors. This is 27% below median its historical median of 22.04. Over the past decade, The Searle Co's EBITDA Margin % has ranged from 16.10 to 26.61. According to the industry distribution chart, The Searle Co ranks #312 out of 961 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is The Searle Co's EBITDA Margin % too high?
The Searle Co's current EBITDA Margin % of 16.04% is 27% below median its 10-year median of 22.04. Over the past 10 years, this metric has ranged from a low of 16.10 to a high of 26.61. The Drug Manufacturers industry median EBITDA Margin % is 12.49. The Searle Co's value of 16.04% is 28.4% above this industry median. Based on the distribution chart, The Searle Co ranks #312 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, The Searle Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Searle Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, The Searle Co ranks #312 out of 961 companies for EBITDA Margin %. This puts The Searle Co in the upper half of its industry. The industry median EBITDA Margin % is 12.49. The Searle Co's value of 16.04% is 28.4% above this benchmark. Historically, The Searle Co's own EBITDA Margin % has ranged from 16.10 to 26.61 over the past decade. While the company's 10-year median is 22.04 vs. the industry median of 12.49, The Searle Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Searle Co's current EBITDA Margin % of 16.04% is 28.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on The Searle Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Searle Co's current EBITDA Margin % is 16.04%, which is 27% below median its own 10-year median of 22.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Searle Co stock overvalued right now?
Based on GuruFocus' analysis, The Searle Co (KAR:SEARL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨76.13, compared to a current price of ₨92.30 — trading 21.2% above its estimated fair value. The current EBITDA Margin % is 16.04%, which is 27% below median its 10-year median of 22.04 and 28.4% above the Drug Manufacturers industry median of 12.49. The Searle Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For The Searle Co (KAR:SEARL), the current EBITDA Margin % is 16.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Searle Co (KAR:SEARL) Overvalued in 2026?
Based on GuruFocus' analysis, The Searle Co stock appears to be overvalued.
The current stock price of ₨92.30 is trading 21.2% above its estimated GF Value™ of ₨76.13.
GuruFocus considers The Searle Co to be Modestly Overvalued.
Key valuation signals for KAR:SEARL:
EBITDA Margin %: 16.04% (27% below median its 10-year median of 22.04)
GF Value™: ₨76.13 vs. price of ₨92.30 (21.2% above fair value)
Industry Position: 28.4% above the Drug Manufacturers median (#312 of 961)
No single metric tells the full story. See the KAR:SEARL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Searle Co Ltd is principally engaged in the manufacturing and sale of pharmaceutical, consumer health, and nutritional products. It manufactures and sells products such as Semavi, Dalimab, Extor, Tramal, Rotec, Hylixi, Emsyn, and many more, focusing on various therapeutic areas like cardiovascular, antibiotics, nutrition, respiratory care, gastroenterology, oncology, hepatology, neurology and psychiatry, probiotics, antibiotics, and nutritional care. Additionally, the group offers medical devices and disposables, health supplements, and various nutritional consumable products. The majority of the group's revenue consists of pharmaceutical sales. Geographically, it generates maximum revenue from Pakistan, and rest from Sri Lanka, Cambodia, Myanmar, Oman, Vietnam, and other countries.
73GF Score
Get the complete analysis for KAR:SEARL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:SEARL has been successfully added to your 
